A. De Giorgi, M. Guarino, B. Boari, R. Cappadona, E. Maietti, F. Fabbian, R. Manfredini
{"title":"Takotsubo cardiomyopathy, acute myocardial infarction and dyslipidaemia: a comparison of studies","authors":"A. De Giorgi, M. Guarino, B. Boari, R. Cappadona, E. Maietti, F. Fabbian, R. Manfredini","doi":"10.1080/17584299.2016.1261959","DOIUrl":null,"url":null,"abstract":"Abstract Background: Takotsubo cardiomyopathy (TTC) and acute myocardial infarction (AMI) share similar clinical presentation and risk of death, although one of the most important differences is the absence of obstructive coronary disease in TTC. We analysed the available literature and evaluated the prevalence of dyslipidaemia in patients with TTC compared with patients with AMI. Methods: A MEDLINE literature search to identify relevant papers focused on TTC and AMI was performed, evaluating the prevalence of dyslipidaemia in both groups. Systematic reviews, meta-analyses, controlled trials, cohort studies and case-control studies were considered for inclusion. We focused on studies reporting precise data on the prevalence of dyslipidaemia for both groups. Results: Out of a total of 511 articles found, 207 case reports, 24 comments, 56 letters and 57 articles in languages other than English were excluded. Of the remaining 167 papers, 23 articles providing the required information were selected. They included and compared 2247 TTC and 19,843 AMI patients. Cases with dyslipidaemia were 734 (32.7%) in the TTC group and 6592 (33.2%) in the AMI group. Conclusions: Patients with TTC showed a prevalence of dyslipidaemia comparable with that of patients with AMI. The prevalence of dyslipidaemia and clinical outcome in TTC and AMI may represent unrelated issues. It is likely that for TTC patients, other conditions and comorbidities, rather than dyslipidaemia alone and/or other established risk factors, are responsible for a risk of death comparable with that of AMI.","PeriodicalId":55252,"journal":{"name":"Clinical Lipidology","volume":"4 1","pages":"33 - 38"},"PeriodicalIF":0.0000,"publicationDate":"2016-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Lipidology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/17584299.2016.1261959","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 2
Abstract
Abstract Background: Takotsubo cardiomyopathy (TTC) and acute myocardial infarction (AMI) share similar clinical presentation and risk of death, although one of the most important differences is the absence of obstructive coronary disease in TTC. We analysed the available literature and evaluated the prevalence of dyslipidaemia in patients with TTC compared with patients with AMI. Methods: A MEDLINE literature search to identify relevant papers focused on TTC and AMI was performed, evaluating the prevalence of dyslipidaemia in both groups. Systematic reviews, meta-analyses, controlled trials, cohort studies and case-control studies were considered for inclusion. We focused on studies reporting precise data on the prevalence of dyslipidaemia for both groups. Results: Out of a total of 511 articles found, 207 case reports, 24 comments, 56 letters and 57 articles in languages other than English were excluded. Of the remaining 167 papers, 23 articles providing the required information were selected. They included and compared 2247 TTC and 19,843 AMI patients. Cases with dyslipidaemia were 734 (32.7%) in the TTC group and 6592 (33.2%) in the AMI group. Conclusions: Patients with TTC showed a prevalence of dyslipidaemia comparable with that of patients with AMI. The prevalence of dyslipidaemia and clinical outcome in TTC and AMI may represent unrelated issues. It is likely that for TTC patients, other conditions and comorbidities, rather than dyslipidaemia alone and/or other established risk factors, are responsible for a risk of death comparable with that of AMI.
期刊介绍:
The Journal of Clinical Lipidology is published to support the diverse array of medical professionals who work to reduce the incidence of morbidity and mortality from dyslipidemia and associated disorders of lipid metabolism. The Journal''s readership encompasses a broad cross-section of the medical community, including cardiologists, endocrinologists, and primary care physicians, as well as those involved in the treatment of such disorders as diabetes, hypertension, and obesity. The Journal also addresses allied health professionals who treat the patient base described above, such as pharmacists, nurse practitioners and dietitians. Because the scope of clinical lipidology is broad, the topics addressed by the Journal are equally diverse. Typical articles explore lipidology as it is practiced in the treatment setting, recent developments in pharmacological research, reports of treatment and trials, case studies, the impact of lifestyle modification, and similar academic material of interest to the practitioner. While preference is given to material of immediate practical concern, the science that underpins lipidology is forwarded by expert contributors so that evidence-based approaches to reducing cardiovascular and coronary heart disease can be made immediately available to our readers. Sections of the Journal will address pioneering studies and the clinicians who conduct them, case studies, ethical standards and conduct, professional guidance such as ATP and NCEP, editorial commentary, letters from readers, National Lipid Association (NLA) news and upcoming event information, as well as abstracts from the NLA annual scientific sessions and the scientific forums held by its chapters, when appropriate.